Contacts

Partial exercise of the over-allotment option and implementation of a liquidity agreement

November 5, 2018

Partial exercise of the over-allotment option
Final amount of the share issue increased to €31.4m
Implementation of a liquidity agreement with Kepler Cheuvreux


Jacou, France, November 5, 2018 – MedinCell, a technological pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, announced today that Crédit Agricole Corporate and Investment Bank, acting as the stabilization agent, in the name and on behalf of the Joint Global Coordinators and Joint Bookrunners, has exercised in part the overallotment option in connection with its initial public offering on the Compartment C of the regulated market Euronext in Paris (“Euronext Paris”), resulting in the issuance of 194,946 additional new shares at the offer price of €7.25 per share representing a total amount of € 1,413,358.50.
As a result, the total number of MedinCell new shares offered in the context of its initial public offering stands at 4,332,877 shares, bringing the size of the offer to € 31,413,358.25. MedinCell’s share capital comprises 20,073,318 shares. MedinCell also announces that it has appointed Kepler Cheuvreux to set up a liquidity agreement in compliance with the AMF (French Regulator) decision n° 2018-01 dated July 2, 2018. The liquidity agreement will be entered into, with effect from November 5, 2018. An amount of € 200,000 has been allocated to the liquidity account for the purposes of this agreement.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.